Loading...
•
Jun 30, 2020
UroGen Q2 2020 Earnings Report
UroGen reported second quarter 2020 financial results and provided recent corporate developments.
Key Takeaways
UroGen Pharma reported net product sales of Jelmyto of approximately $371,500 for the second quarter ended June 30, 2020. The company's cash, cash equivalents and marketable securities totaled $151.6 million as of June 30, 2020.
Received U.S. FDA Approval of Jelmyto, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
Successfully Commenced Launch of Jelmyto on June 1st as Planned; Initial Commercial Performance Demonstrates Strong Execution
Announced Positive Complete Response and Durability Data of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
On Track to Commence Pivotal Phase 3 Trial by Year End
Revenue by Segment
Forward Guidance
UroGen adjusted expense guidance down for 2020, driven by change in estimated non-cash share-based compensation expense for 2020. UroGen now expects 2020 total operating expenses in the range of $143 to $153 million, including non-cash share-based compensation expense of $30 to $34 million, subject to market conditions.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...